Theodore Mazzone

Cell surface proteoglycans modulate net synthesis and secretion of macrophage apolipoprotein E.

Using a macrophage cell line that constitutively expresses a human apolipoprotein E (apoE) cDNA, we have investigated the post-translational metabolism of endogenously produced apoE. Inhibition of lysosomal or cysteine proteases led to significant inhibition of apoE degradation but did not increase apoE secretion, indicating that cellular degradation is not limiting for apoE secretion in macrophages. Treatment of macrophages with inhibitors of proteoglycan synthesis (4-methylumbelliferyl-β-D-xyloside) or sulfation (sodium chlorate) enhanced the release of apoE from cells and significantly attenuated the increase in secretion produced by incubation with phosphatidylcholine vesicles (PV). These observations suggested that a significant fraction of the apoE retained by cells (and released by incubation with PV) was associated with proteoglycans. Treatment of cells with exogenous heparinase led to a greater than 4-fold increase in apoE secretion and similarly attenuated the response to PV, suggesting that apoE was trapped in an extracellular proteoglycan matrix. This conclusion was confirmed in studies showing that PV could enhance the release of apoE from cells during an incubation at 4°C, but this enhanced release was abolished in proteoglycan-depleted cells. Incubation with lactoferrin at 4 or 37°C produced a similar decrement in cellular apoE, again indicating the existence of a cell surface pool of apoE. Pulse-chase studies showed that the apoE trapped in the proteoglycan matrix was susceptible to rapid cellular degradation such that net synthesis of apoE (secreted plus cell-associated) was increased significantly in proteoglycan-depleted cells compared with control cells as early as 45 min during a chase period.

Degradation of Macrophage ApoE in a Nonlysosomal Compartment REGULATION BY STEROLS

Macrophage-derived apoE has been shown to play an important role in the susceptibility of the vessel wall to atherosclerosis. Previous studies have shown that macrophage sterol content modulates apoE synthesis and secretion, associated with a large transcriptional response of the apoE gene. The current studies were undertaken to evaluate the existence of additional post-transcriptional regulatory loci for the effect of sterols on apoE synthesis and secretion. Using a macrophage cell line transfected to constitutively express an apoE cDNA to facilitate detection of a post-transcriptional regulatory locus, we demonstrated that preincubations in 25-hydroxycholesterol and cholesterol lead to increased apoE secretion in pulse/chase experiments. Examination of cell lysates in these experiments showed that apoE not secreted by control cells was degraded and not detectable, suggesting that the preincubation in sterols increased secretion by decreasing degradation of newly synthesized apoE. The measurement of total protein and apoE degradation in cell fractions revealed an intermediate density fraction that degraded significant amounts of newly synthesized total protein and newly synthesized apoE. In this fraction, degradation of total protein and apoE was unaffected by chloroquine but was substantially reduced by N-acetyl-Leu-Leu-norleucinal plusN-acetyl-Leu-Leu-methioninal or by lactacystin, suggesting the involvement of proteasomes. Preincubation in sterol/oxysterol or acetylated low density lipoprotein did not modify total protein degradation by this fraction but inhibited apoE degradation. Similar results were obtained using intermediate density fractions isolated from human monocyte-derived macrophages. The results of our studies indicate that newly synthesized apoE in the macrophage can be degraded in an intermediate density nonlysosomal cellular compartment, which is sensitive to proteasomal inhibitors. Alteration of cellular lipid homeostasis by preincubation in sterol/oxysterol or acetylated low density lipoprotein inhibits apoE, but not total protein, degradation in this fraction. Inhibition of the degradation of apoE in this fraction likely contributes to the increased apoE secretion observed in sterol-enriched cells.

Lipoprotein Lipase Reduces Secretion of Apolipoprotein E from Macrophages

Macrophages are a significant source of lipoprotein lipase (LPL) and apolipoprotein E (apo E) in the developing arterial wall lesion, and each of these proteins can importantly modulate lipid and lipoprotein metabolism by arterial wall cells. LPL and apo E share a number of cell surface binding sites, including proteoglycans, and we have previously shown that proteoglycans are important for modulating net secretion of apoprotein E from macrophages. We therefore evaluated a potential role for LPL in modulating net secretion of macrophage-derived apo E. In pulse-chase experiments, addition of LPL during the chase period produced a decrease in secretion of apoprotein E from human monocyte-derived macrophages, from the human monocytic THP1 cell line, and from J774 cells transfected to constitutively express a human apo E cDNA. LPL similarly reduced apo E secretion when it was prebound to the macrophage cell surface at 4u2009°C. A native LPL particle was required to modulate apo E secretion; addition of monomers and aggregates did not produce the same effect. Depletion of cell surface proteoglycans by a 72-h incubation in 4-methylumbelliferyl-β-d-xyloside did not attenuate the ability of LPL to reduce apo E secretion. However, addition of receptor-associated protein attenuated the effect of LPL on apo E secretion. Although LPL could mediate removal of exogenously added apo E from the culture medium, detailed pulse-chase analysis suggested that it primarily prevented release of newly synthesized apo E from the cell layer. Cholesterol loading of cells or antibodies to the low density lipoprotein receptor attenuated LPL effects on apo E secretion. We postulate that LPL sequesters endogenously synthesized apo E at the cell surface by a low density lipoprotein receptor-dependent mechanism. Such post-translational regulation of macrophage apo E secretion by LPL could significantly influence apo E accumulation in arterial vessel wall lesions.

Plasma Lipids and Stroke

High plasma levels of lipids are an important modifiable risk factor for coronary heart disease, but are not established as a risk factor for stroke. Pathophysiologic evidence that links lipids to major systemic artery disease, and the results of clinical trials of coronary heart disease prevention in relation to lipid-lowering suggest that lipids may play an important role in the causation of stroke. We discuss the controversy concerning plasma lipids as a risk factor for stroke. A clinical trial targeted at lowering levels of lipids with the aim of primary stroke prevention would be a timely and important contribution. Armed with this information, we could further clarify the plasma lipid–stroke controversy and move into the 21st century with a better understanding of stroke prevention.

Scavenger Receptors in Atherosclerosis New Answers, New Questions

The existence of a cell surface receptor, now known as the macrophage scavenger receptor A I/II (MSR-A), was inferred from early studies based on ligand binding analyses. Description of this binding activity, with acetylated low density lipoprotein (LDL) used as a ligand, was important because it provided a mechanism for the formation of foam cells in vivo and because the activity of this receptor was not downregulated by expanding cellular cholesterol stores as had been recently shown for the LDL receptor. The presence of acetylated LDL receptor binding activity, predominantly on macrophage-type cells, helped to underscore the importance of the macrophage in atherogenesis and stimulated further investigation of macrophage function in the vessel wall. The description of this activity also helped to fuel investigative efforts to identify a potential in vivo ligand, and the various forms of oxidized LDL were soon suggested as physiological ligands for this receptor. Thus, the MSR-A has already shaped investigative efforts into the mechanisms of atherosclerosis. Now that MSR-A has been cloned, attempts to further understand its role in atherogenesis with the use of mice deficient in its expression have been undertaken.nnAn early report by Suzuki et al1 demonstrated that compared with control apolipoprotein E (apoE)–knockout mice, mice with macrophage scavenger receptor A I/II (MSR-A) deficiency, on an apoE-deficient background, exhibited a 60% decrease in lesions; this observation was consistent with a proatherogenic role for this receptor in vivo. There were a number of surprising findings in their study. Even though acetylated LDL degradation by macrophages was reduced substantially, there was no difference in the metabolism of acetylated LDL in vivo. In spite of this, the plasma cholesterol level in double-knockout mice was higher than in apoE-knockout mice. These double-knockout mice were also found to have increased susceptibility to infection, and the macrophages …

Evaluation of the role of Ap1-like proteins in the enhanced apolipoprotein E gene transcription accompanying phorbol ester induced macrophage differentiation

Differentiation of THP1 monocytes to a macrophage phenotype is accompanied by increased apolipoprotein E gene transcription. Using transfection analysis with 5 deletion mutations of the 5 control region of the apo E gene in THP1 cells, we show that the -651 to +86 chloramphenicol acetyltransferase (CAT) construct is efficiently expressed in the monocyte; as has been reported for other cell types. Further, we found that an 176 bp region between -623 to -447 was required for the induction of apolipoprotein E gene transcription during 12-O-tetradecanoylphorbol-13-acetate-induced differentiation of monocytes to macrophages. Gel-retardation patterns of the apolipoprotein E promoter region using nuclear extracts from differentiated or undifferentiated THP1 cells revealed altered binding of Ap1-like nuclear factor/s to the -620 to -583 bp region after macrophage differentiation. Mutation of an Ap1 element at position -602 abolished specific binding of Ap1-like proteins to the -620 to -583 bp fragment of the apo E gene and significantly reduced expression of a -623 to +86 apo E-CAT construct during differentiation. These data indicate that differentiation-related expression of the apolipoprotein E gene following phorbol ester stimulation is transduced by gene elements between -623 and -447. Furthermore, the data indicate that transcriptional activation of the apo E gene during macrophage differentiation is associated with induction of Ap1-like proteins which bind to the Ap1 response element present at -602 in the apolipoprotein E gene and importantly contribute to enhanced gene expression.

Sterols and inhibitors of sterol transport modulate the degradation and secretion of macrophage ApoE: requirement for the C-terminal domain

Macrophage-derived apoE, produced in the vessel wall, may have important effects during atherogenesis. The production of apoE by macrophages can be regulated at a transcriptional level by cellular differentiation state, cytokines and sterol loading. In addition, there are post-transcriptional and post-translational loci for regulation. We have recently identified an intermediate density cell membrane fraction in which the degradation of apoE can be modulated by sterols. Suppressing degradation of apoE in this fraction by pre-incubating cells in sterols led to enhanced apoE secretion. In this report we demonstrate that the suppressive effect of sterols on the degradation of newly synthesized apoE in this fraction depends on the presence on its C-terminal domain, by studying a macrophage cell line transfected to express a mutant form of apoE in which amino acids beyond amino acid 202 were deleted. In addition, two modulators of cellular sterol transport, progesterone and U1866A, inhibited the degradation of full-length apoE. In contrast, incubation of cells in the acyl-CoA:cholesterol acyltransferase inhibitor S58035 did not influence apoE degradation. As would be predicted based on the results of degradation assays, U1866A, but not S58035, increased the secretion of apoE from a cell line transfected to constitutively express full-length apoE cDNA. The effect of U1866A on apoE degradation, like the effect of sterol, required the presence of the apoE C-terminal domain. Our results indicate that alteration of intracellular sterol homeostasis by pre-incubation in sterols or by drugs that modify the subcellular transport of sterol, modulates the susceptibility of apoE to degradation and that this modulation requires the presence of C-terminal lipid binding domains.

Platelet-Derived Growth Factor Enhances Sp1 Binding to the LDL Receptor Gene

We have previously demonstrated that growth activation of quiescent cells enhances LDL receptor gene transcription and that the proximal 5 flanking region of the LDL receptor gene could transduce a platelet-derived growth factor (PDGF) response. This portion of the LDL receptor gene encompasses a previously characterized sterol response element and an adjacent Sp1 binding site. By use of mobility shift analyses we show that PDGF activation of quiescent cells enhances binding of Sp1 to the LDL receptor gene. Transfection analyses indicated that the Sp1 site, but not the sterol response element binding protein site, could confer PDGF responsiveness to a heterologous promoter in quiescent cells. Furthermore, cotransfection of an LDL receptor reporter gene (containing -141 to +35 bp of the LDL receptor gene promoter) along with an expression construct coding for high-level constitutive expression of an Sp1 cDNA led to marked enhancement in expression of the LDL receptor reporter gene in quiescent cells. Increased Sp1 binding due to PDGF could be due to enhanced production of Sp1; alternatively, posttranslational activation of binding could be involved. Western blot analysis showed no difference in Sp1 abundance in quiescent cells versus PDGF-stimulated cells, suggesting a posttranslational mechanism for activation of Sp1 binding by growth induction. Our data demonstrate that PDGF stimulation of quiescent cells leads to enhanced Sp1 binding to the LDL receptor gene. This enhanced binding could participate in PDGF induction of LDL receptor gene transcription.